Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2015:2015:871641.
doi: 10.1155/2015/871641. Epub 2015 Mar 8.

Comment on "5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity"

Thomas Mørch Frøsig  1 , Sine Reker Hadrup  1
Affiliations
Comment

Comment on "5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity"

Thomas Mørch Frøsig et al. Mediators Inflamm. 2015.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Stübig T., Badbaran A., Luetkens T., et al. 5-Azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity. Mediators of Inflammation. 2014;2014:12. doi: 10.1155/2014/418292.418292 - DOI - PMC - PubMed
    1. Gang A. O., Frøsig T. M., Brimnes M. K., et al. 5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies. Blood Cancer Journal. 2014;4(3, article e197) doi: 10.1038/bcj.2014.14. - DOI - PMC - PubMed
    1. Silverman L. R., Demakos E. P., Peterson B. L., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. Journal of Clinical Oncology. 2002;20(10):2429–2440. doi: 10.1200/jco.2002.04.117. - DOI - PubMed
    1. Qiu X., Hother C., Ralfkiaer U. M., et al. Equitoxic doses of 5-Azacytidine and 5-Aza-2'deoxycytidine induce diverse immediate and overlapping heritable changes in the transcriptome. PLoS ONE. 2010;5(9) doi: 10.1371/journal.pone.0012994.e12994 - DOI - PMC - PubMed
    1. Dubovsky J. A., McNeel D. G., Powers J. J., Gordon J., Sotomayor E. M., Pinilla-Ibarz J. A. Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen. Clinical Cancer Research. 2009;15(10):3406–3415. doi: 10.1158/1078-0432.ccr-08-2099. - DOI - PubMed

MeSH terms

Substances